Brooklyn Bodega Sold Fake Injectable Peptides, Lab Tests Reveal

A Brooklyn bodega selling injectable peptides is distributing products that contain none of the active ingredients listed on their labels, according to laboratory tests. The findings expose a precarious grey market where consumers pay for high-end wellness supplements that are, in reality, biologically inert.

WIRED purchased four types of injectable peptides from Mr. Green, a bodega located on Bedford Avenue in Brooklyn, and submitted them to Finnrick, an independent testing startup. The lab results revealed that every single sample—including PT-141 for libido, BPC-157 for healing, NAD+ for cellular repair, and retatrutide for weight loss—failed to contain its labeled active ingredient. While the samples were not found to be actively harmful, showing only low levels of heavy metals and endotoxins, they were described as "duds."

The 'Research' Loophole

This fraudulent activity is facilitated by a common legal maneuver in the supplement industry. The products at Mr. Green were labeled "for research use only," a designation used by sellers to attempt to shield themselves from legal liability regarding human consumption and to evade strict pharmaceutical regulations. By framing these substances as research chemicals rather than medicine, vendors can bypass the oversight typically required for injectable drugs.

This trend has coincided with a broader surge in peptide popularity, driven in part by endorsements from high-profile figures such as Robert F. Kennedy Jr. and Joe Rogan. While some peptides are FDA-approved, such as insulin or GLP-1 weight-loss drugs, many of the "buzzy" compounds sold in grey markets have no regulatory approval for human use in the United States.

Industry Implications

According to Raphaël Mazoyer, CEO of Finnrick, the rise of "turnkey services" has lowered the barrier to entry, allowing nearly anyone to launch a peptide business. Mazoyer suggests these businesses often rely on the same unreliable upstream vendors, leading to widespread quality issues. Marco Krause, CEO of the laboratory that performed the tests for Finnrick, noted that their process is a "label claim analysis," where they verify if a compound matches the standard of what it claims to be.

This incident highlights a dangerous lack of regulation and transparency. When products are sold through loopholes, buyers have no guarantee of purity, potency, or safety. While the Brooklyn samples were ineffective rather than toxic, the lack of oversight means consumers are routinely exposed to the risk of corrupted or mislabeled chemicals.

What to Watch

As the demand for performance-enhancing and weight-loss peptides grows, the gap between viral marketing and regulatory enforcement continues to widen. It remains unclear if other Brooklyn vendors are sourcing from the same upstream suppliers as Mr. Green, or if this is an isolated case of fraud. For now, the "research use only" label remains a primary red flag for consumers seeking substances that bypass medical supervision.